Aveanna Healthcare (NASDAQ:AVAH) Major Shareholder Paul Vigano Sells 3,000,000 Shares

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) major shareholder Paul Vigano sold 3,000,000 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $8.01, for a total transaction of $24,030,000.00. Following the sale, the insider directly owned 190,130 shares in the company, valued at $1,522,941.30. This trade represents a 94.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Aveanna Healthcare Stock Up 3.7%

Aveanna Healthcare stock traded up $0.33 during trading hours on Thursday, hitting $9.19. The stock had a trading volume of 1,002,532 shares, compared to its average volume of 1,480,237. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 5.35. The stock has a market capitalization of $2.00 billion, a P/E ratio of 7.78, a price-to-earnings-growth ratio of 0.88 and a beta of 1.89. Aveanna Healthcare Holdings Inc. has a 12-month low of $3.73 and a 12-month high of $10.32. The stock’s 50-day moving average price is $7.25 and its 200-day moving average price is $7.56.

Aveanna Healthcare (NASDAQ:AVAH) last posted its quarterly earnings results on Thursday, May 14th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.05. The firm had revenue of $647.91 million for the quarter, compared to analysts’ expectations of $613.22 million. Aveanna Healthcare had a net margin of 10.37% and a return on equity of 124.68%. The business’s revenue was up 15.9% on a year-over-year basis. Equities research analysts anticipate that Aveanna Healthcare Holdings Inc. will post 0.65 EPS for the current fiscal year.

Institutional Trading of Aveanna Healthcare

A number of hedge funds have recently bought and sold shares of AVAH. Vanguard Group Inc. lifted its holdings in Aveanna Healthcare by 38.0% in the fourth quarter. Vanguard Group Inc. now owns 5,577,010 shares of the company’s stock valued at $45,564,000 after acquiring an additional 1,535,351 shares during the period. Geode Capital Management LLC increased its position in shares of Aveanna Healthcare by 17.7% during the 4th quarter. Geode Capital Management LLC now owns 1,849,057 shares of the company’s stock valued at $15,110,000 after purchasing an additional 278,429 shares during the last quarter. AustralianSuper Pty Ltd purchased a new stake in shares of Aveanna Healthcare during the 3rd quarter valued at about $15,743,000. Nuveen LLC lifted its stake in shares of Aveanna Healthcare by 135.9% in the 4th quarter. Nuveen LLC now owns 1,571,308 shares of the company’s stock worth $12,838,000 after purchasing an additional 905,316 shares during the period. Finally, State Street Corp lifted its stake in shares of Aveanna Healthcare by 20.9% in the 4th quarter. State Street Corp now owns 1,483,265 shares of the company’s stock worth $12,118,000 after purchasing an additional 256,392 shares during the period. Hedge funds and other institutional investors own 87.96% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on AVAH shares. Raymond James Financial raised Aveanna Healthcare from an “outperform” rating to a “strong-buy” rating and set a $13.00 target price for the company in a report on Friday, March 20th. Stephens raised Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $10.00 to $11.00 in a research report on Friday, May 15th. Truist Financial lifted their price objective on Aveanna Healthcare from $8.00 to $9.00 and gave the stock a “hold” rating in a report on Wednesday, May 20th. Barclays lowered their target price on shares of Aveanna Healthcare from $9.50 to $9.00 and set an “overweight” rating on the stock in a research note on Monday, May 18th. Finally, Weiss Ratings downgraded shares of Aveanna Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, Aveanna Healthcare has an average rating of “Moderate Buy” and a consensus target price of $10.50.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.